Add to a list

Inactive Instrument

LOTUS PHARM Stock OTC Bulletin Board

LTUS

US5457151042

Pharmaceuticals

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE

Lotus Pharmaceuticals Inc is a company mainly engaged in development, manufacture, and sales of pharmaceuticals. The Company produces crude medicine and drugs in forms of tablets, capsules, granules, eye-drops, and freeze-dried powder injection. The Company's drug development is focused on the treatment of cerebro-cardiovascular disease, asthma, and diabetes. The Company operated in two business segment Wholesales segment and Retail segment. The Company's products include Maixin-valsartan capsules for the treatment of hypertension, Muxineye drops for the treatment of glaucoma and Yipubishan-octreotide Acetate Injection solution for the treatment of gastric ulcers. The Company mainly conducts its businesses in the domestic market and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Maximize my profits

Market Cap	9.74M 8.65M 8.02M 7.3M 13.77M 924M 13.99M 96.42M 37.8M 482M 36.54M 35.76M 1.54B	P/E 2009	3.88x	P/E 2010	4.84x
Enterprise Value	14.38M 12.78M 11.85M 10.78M 20.34M 1.37B 20.67M 142M 55.85M 712M 53.98M 52.83M 2.27B	EV / Sales 2009	1.02x	EV / Sales 2010	0.95x
Free-Float	99%	Yield 2009 *	-	Yield 2010	-

23-07-31	Amarin, Lotus Pharmaceuticals Agree to Exclusive Vazkepa Distribution Deal in 10 Asian Countries	MT
21-11-26	Thai oil firm PTT expands pharma business with $475 million Alvogen deal	RE
21-09-28	Lotus Pharmaceuticals : Temasek-backed Vertex expects at least $400 million in new S.E.Asia/India fund	RE
12-05-16	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS from LTUSE	CI
12-04-19	Lotus Pharmaceuticals, Inc. has Changed its Ticker to LTUS.E from LTUS	CI

Dec. 30	Lotus Pharmaceutical Supports Street Medicine Program to Expand Access to Care for Those Most in Need	AQ
25-10-06	Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection	AQ
25-08-12	Lotus Pharmaceutical Achieves New First-Half Record in Revenue for 2025, While Q2 Impacted by FX and Timing of Lenalidomide Sales	AQ
25-02-21	Lotus announces FDA acceptance of Potential First-to-File ANDA Submission for Voclosporin soft gelatin capsules, a generic equivalent to Lupkynis	AQ
24-11-08	Lotus Achieves Second-Highest Quarterly Performance in Company History with 3Q24 Financial Results	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.43%	+6.59%	+56.57%	+106.64%	1,120B
JOHNSON & JOHNSON	+0.90%	-2.25%	+32.26%	+63.73%	616B
ABBVIE INC.	+0.71%	+3.24%	+24.33%	+91.33%	504B
ROCHE HOLDING AG	-0.13%	+5.98%	+33.66%	+50.18%	367B
MERCK & CO., INC.	+0.52%	+0.24%	+72.13%	+40.11%	360B
NOVARTIS AG	-0.95%	+4.70%	+19.65%	+42.71%	288B
ASTRAZENECA PLC	-1.98%	+3.73%	-0.89%	+10.43%	258B
AMGEN INC.	-0.35%	+4.25%	+44.74%	+52.06%	234B
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+27.18%	+94.07%	194B
Average	-0.18%	+3.61%	+34.40%	+61.25%	437.88B
Weighted average by Cap.	+0.13%	+3.83%	+39.34%	+71.82%

	2009	2010
Net sales	57.82M 51.4M 47.64M 43.35M 81.79M 5.49B 83.11M 573M 225M 2.86B 217M 212M 9.13B	72.7M 64.62M 59.89M 54.49M 103M 6.9B 104M 720M 282M 3.6B 273M 267M 11.48B
Net income	16.43M 14.61M 13.54M 12.32M 23.24M 1.56B 23.62M 163M 63.8M 814M 61.67M 60.36M 2.59B	14.42M 12.82M 11.88M 10.81M 20.4M 1.37B 20.73M 143M 56.01M 714M 54.14M 52.98M 2.28B
Net Debt	5.29 4.71 4.36 3.97 7.49 502.43 7.61 52.43 20.56 262.19 19.87 19.44 835.81	4.65 4.13 3.83 3.48 6.57 441.01 6.68 46.02 18.04 230.14 17.44 17.07 733.64

LOTUS PHARM Stock OTC Bulletin Board

Stocks

LTUS

US5457151042

Pharmaceuticals

Valuation: LOTUS PHARM

Latest news: LOTUS PHARM

Press Releases: LOTUS PHARM

Managers and Directors: LOTUS PHARM

Generic Pharmaceuticals

Financials

Company Profile